Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.

Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.

Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127.

PMID:
21716274
2.
3.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ.

J Thromb Haemost. 2007 Dec;5(12):2429-36.

4.

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

Kelly RP, Close SL, Farid NA, Winters KJ, Shen L, Natanegara F, Jakubowski JA, Ho M, Walker JR, Small DS.

Br J Clin Pharmacol. 2012 Jan;73(1):93-105. doi: 10.1111/j.1365-2125.2011.04049.x.

5.

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.

Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.

Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268.

PMID:
21178986
6.

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.

J Am Coll Cardiol. 2013 Feb 26;61(8):872-9. doi: 10.1016/j.jacc.2012.11.040.

7.

Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.

Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.

J Clin Pharmacol. 2012 Oct;52(10):1506-15.

PMID:
22128201
8.

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.

Horenstein RB, Madabushi R, Zineh I, Yerges-Armstrong LM, Peer CJ, Schuck RN, Figg WD, Shuldiner AR, Pacanowski MA.

J Clin Pharmacol. 2014 Aug;54(8):865-73. doi: 10.1002/jcph.293.

9.

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.

Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T.

Circ J. 2009 Aug;73(8):1498-503.

10.

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.

Clin Pharmacol Ther. 2007 May;81(5):735-41.

PMID:
17361128
11.

Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.

Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J.

Gene. 2015 Mar 10;558(2):200-7. doi: 10.1016/j.gene.2014.12.051.

PMID:
25542807
12.

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Kim KA, Park PW, Hong SJ, Park JY.

Clin Pharmacol Ther. 2008 Aug;84(2):236-42. doi: 10.1038/clpt.2008.20.

PMID:
18323861
13.

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthélémy O, Beygui F, Gallois V, Montalescot G; CLOVIS-2 Investigators..

JACC Cardiovasc Interv. 2011 Apr;4(4):392-402. doi: 10.1016/j.jcin.2011.03.002.

14.

Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.

Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.

Eur Heart J. 2012 Nov;33(22):2856-2464a. doi: 10.1093/eurheartj/ehs042.

PMID:
22374717
15.

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.

Wu J, Jia LT, Shao LM, Chen JM, Zhong DD, Xu S, Cai JT.

Eur J Clin Pharmacol. 2013 Feb;69(2):179-87. doi: 10.1007/s00228-012-1329-z.

PMID:
22706585
17.

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

Kim HS, Lim Y, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG.

Br J Clin Pharmacol. 2016 Feb;81(2):301-12. doi: 10.1111/bcp.12794.

18.

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL.

Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157.

19.

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.

JACC Cardiovasc Interv. 2011 Apr;4(4):381-91. doi: 10.1016/j.jcin.2010.12.010.

20.

Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.

Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M.

Clin Pharmacol Ther. 2011 Jan;89(1):65-74. doi: 10.1038/clpt.2010.219.

PMID:
20844485

Supplemental Content

Support Center